Current Research Studies

Cancer - ANBL1232: Utilizing Response - and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma - a Groupwide Historically Controlled Phase 3 Study

Condition or Therapy:

Ganglioneuroblastoma, neuroblastoma


Cancer and Blood Disorders
Study Number: ANBL1232

What is the goal of this study?

The goal of this study is to use response- and biology-based, risk-guided therapy in treating patients with non-high-risk neuroblastoma instead of using standard treatment.

Who can join the study?

This study may be a good fit for children who:

  • are up to 18 months old, and
  • have been newly diagnosed with v-myc avian myelocytomatosis viroal oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma (International Classification of Diseases for Oncology morphology 9500/3) or MYCN non-amplified ganglioneuroblastoma.

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins